Cambridge Antibody and Dyax amend antibody product agreement.
The new agreement extends the arrangement that was previously announced in January 2003 and grants Dyax, amongst other benefits, an increased number of options for licences to develop therapeutic and diagnostic antibody products under Cambridge Antibody's patents for Dyax's own use and on behalf of its partners. Cambridge Antibody and Dyax have further agreed that, as a result of this agreement, royalties will not be due to Dyax in respect of HUMIRA.
Peter Chambre, Cambridge Antibody's Chief Executive Officer, commented: "We are delighted to have expanded our agreement with Dyax and to have resolved the position with respect to HUMIRA."
Henry E. Blair, Dyax's Chairman, President and Chief Executive Officer, commented "We are very pleased to expand further our licensing arrangement with Cambridge Antibody. This expansion significantly increases the potential number of antibody products Dyax can discover both for our own pipeline and for collaborators."
Cambridge Antibody is a leader in the discovery and development of human therapeutic antibodies and has an advanced proprietary platform technology for rapidly isolating human monoclonal antibodies using phage display and ribosome display systems. Cambridge Antibody has extensive phage antibody libraries, currently incorporating more than 100 billion distinct antibodies. These libraries form the basis for the Company's strategy to develop a portfolio of antibody-based drugs.
HUMIRA, their leading antibody, isolated and optimised in collaboration with Abbott has been approved by the United States Food and Drug Administration for marketing in the United States as a treatment for rheumatoid arthritis.
Eight further Cambridge Antibody-derived human therapeutic antibodies are at various stages of clinical trials. There are five candidate therapeutic antibodies in pre-clinical development.
Cambridge Antibody has alliances with a number of pharmaceutical and biotechnology companies to discover, develop and commercialise human monoclonal antibody-based products. Cambridge Antibody has co-development programmes with Amgen, Amrad, Elan and Genzyme. The company has also licensed its proprietary technologies to several companies. Cambridge Antibody's licensees include: Abbott, Amgen, Chugai, Human Genome Sciences, Merck & Co, Pfizer and Wyeth Research.
Dyax is principally focused on the discovery, development and commercialization of therapeutics for inflammatory conditions and in oncology. Dyax currently has two recombinant proteins in clinical development, DX-88 and DX-890. DX-88 is being studied in phase II clinical trials for the treatment of hereditary angioedema in collaboration with Genzyme Corporation. Dyax is also studying DX-88 in a phase I/II clinical trial for use during cardiopulmonary bypass surgery. DX-890 is being studied in phase IIa clinical trials for the treatment of cystic fibrosis in collaboration with Debiopharm, S.A. Dyax utilizes its proprietary phage display technology to rapidly identify a broad range of recombinant protein, peptide, and fully human monoclonal antibody compounds that bind with high affinity and specificity to targets of interest, with the objective of selecting those compounds with the greatest potential for advancement into clinical development. Dyax leverages broadly its phage display technology through revenue generating licenses and collaborations in both its core therapeutics area, as well as in non-core areas of affinity separations, diagnostic imaging, and research reagents. Through its subsidiary, Biotage, Inc., Dyax develops, manufactures and sells chromatography separations systems and products to pharmaceutical companies worldwide for drug discovery and purification.
Cambridge Antibody Technology
|Printer friendly Cite/link Email Feedback|
|Publication:||BIOTECH Patent News|
|Date:||Sep 1, 2003|
|Previous Article:||Alnylam licenses intellectual property in RNA interference.|
|Next Article:||Cellomics patents method for detecting the translocation of a cellular component.|
|Dyax expands antibody discovery capabilities.|
|Cambridge Antibody and Dyax expand phage display license.|
|DYAX REPORTS NET LOSS FOR 4TH QTR AND YEAR-END 2002.|